Compounds for increasing the nicotinamide adenine dinucleotide in a subject and methods of use thereof
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that increase the amount of nicotinamide adenine dinucleotide (NAD + ) in a subject. By raising the amount of nicotinamide adenine dinucleotide in a subject, diseases associated with reduced levels of nicotinamide adenine dinucleotide can be treated or prevented. In one aspect, raising the amount of NAD + in a subject can reduce or ameliorate one or more symptoms of Parkinson's disease, Alzheimer's disease, Huntington's disease, Multiple sclerosis, amylotrophic lateral sclerosis, AIDS-induced dementia, or epilepsy.
1 . A compound having a structure I or a pharmaceutically acceptable salt thereof
wherein
R 1 is a phenyl group substituted with at least one alkoxy group, haloalkoxy group, hydroxyl group, alkyl group, haloalkyl group, or an amino group;
R 2 is a substituted or unsubstituted heteroaryl group selected from the group consisting of furyl, pyrimidinyl, tetrazolyl, thienyl, pyridinyl, pyrrolyl, N-methylpyrrolyl, quinolinyl, isoquinolinyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridazinyl, pyrazinyl, indolyl, and indazolyl, the substituted monocyclic heteroaryl group is a heteroaryl group substituted with a group selected from the group consisting of alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, and thiol;
R 3 is a substituted or unsubstituted tetrahydropyranyl group, wherein the substituted tetrahydropyranyl group is a tetrahydropyranyl group substituted with a group selected from the group consisting of alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, and thiol;
r is 1, 2, or 3;
s is 1, 2, or 3; and
t is 0, 1, or 2.
2 . The compound of claim 1 , wherein R 1 has the structure II
wherein
each R 4 is independently an alkoxy group, a haloalkoxy group, a hydroxyl group, an alkyl group, a haloalkyl group, or an amino group; and
n is 1, 2, 3, 4, or 5.
3 . The compound of claim 2 , wherein R 4 is alkoxy or a dialkylamino group and n is 1.
4 . The compound of claim 2 , wherein R 4 is methoxy and n is 1.
5 . The compound of claim 1 , wherein R 2 is a substituted or unsubstituted furyl group or a substituted or unsubstituted thienyl group.
6 . The compound of claim 1 , wherein R 2 is
wherein
R 20 is an alkoxy group, a haloalkoxy group, a hydroxyl group, a halide, an alkyl group, a haloalkyl group, or an amino group.
7 . The compound of claim 1 , wherein R 3 has the structure III
wherein R a to R 13 are independently hydrogen, a C1 to C10 alkyl group, or cycloalkyl group.
8 . The compound of claim 1 , wherein R 3 is
wherein p is 1, 2, 3, or 4, and
q is 0, 1, 2, 3, 4, or 5.
9 . The compound of claim 1 , wherein r is 1 and s is 2.
10 . The compound of claim 1 , wherein
R 1 is a phenyl group substituted with at least one alkoxy group, haloalkoxy group, hydroxyl group, alkyl group, haloalkyl group, or an amino group;
R 2 is a substituted or unsubstituted furyl group or a substituted or unsubstituted thienyl group; and
R 3 has the structure III
wherein R 5 to R 13 are independently hydrogen, a C1 to C10 alkyl group, or cycloalkyl group.
11 . The compound of claim 10 , wherein r is 1, s is 2, and t is 0.
12 . The compound of claim 1 , wherein the compound has the structure IV
wherein
R 2 is a substituted or unsubstituted furyl group or a substituted or unsubstituted thienyl group;
R 4 is an alkoxy group, a haloalkoxy group, a hydroxyl group, an alkyl group, a haloalkyl group, or an amino group; and
R 5 to R 13 are independently hydrogen, a C1 to C10 alkyl group, or cycloalkyl group.
13 . The compound of claim 12 , wherein R 4 is an alkoxy group or a dialkylamino group.
14 . The compound of claim 12 , wherein R 4 is a methoxy group or a dimethylamino group.
15 . The compound of claim 12 , wherein R 2 is an unsubstituted furyl group or a substituted or unsubstituted thienyl group.
16 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
17 . A method for treating or preventing a neurological disease in a subject, the method comprising administering to the subject a compound of claim 1 , wherein the neurological disease comprises Parkinson's disease, Alzheimer's disease Huntington's disease, multiple sclerosis, amylotrophic lateral sclerosis ADS-induced dementia, or epilepsy.